Unlock full details of this profile with our free Lite plan!
Sign Up and Get Free AccessAbout HBM Healthcare Investments
HBM Healthcare Investments is a venture capital firm founded in 2001. It is primarily based out of Zug, Switzerland. As of Apr 2025, HBM Healthcare Investments is an active investor, having invested in 122 companies, with 2 new investments in the last 12 months. It primarily invests in Series C round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and Enterprise Applications. Most recently it led the $200M Series C round of ADARx Pharmaceuticals along with Venrock. This round also saw participation from Vivo Capital and other investors.
Overall, HBM Healthcare Investments portfolio has seen 1 unicorn, 39 IPOs and 34 acquisitions including key companies like Tata 1mg, SpringWorks Therapeutics and argenx. A lot of funds co-invest with HBM Healthcare Investments, with names like Orbimed sharing a substantial percentage of its portfolio.
HBM Healthcare Investments has team of 32 people including 10 partners.
Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series B, Series C & 7 more
Portfolio IPOs
Portfolio Acquisitions
Portfolio Unicorns
HBM Healthcare Investments' List of Top Investments
HBM Healthcare Investments has a portfolio of 122 companies, one of which is a Unicorn. Their most notable investments are in Locus Pharmaceuticals and Broncus.Their portfolio spans across United States, Switzerland, China and 13 more locations. They have invested in Life Sciences, High Tech, Enterprise Applications and 6 other sectors, across stages such as Series B, Series C and 7 more. Here is the list of top investments by HBM Healthcare Investments:1. Tata 1mg
Provider of an online pharmacy with doctor listing and teleconsultation services. It offers pharmacy store where the user to view medicines, compare prices, and purchase online. The user can also upload prescriptions for placing the order. It offers an online doctor consultation and lab test platform that allows users to search for doctors and book appointments. The platform sells fitness supplements, healthcare products, healthcare devices, and alternate medicines.
Key facts about Tata 1mg
- Founded Year: 2015
- Location: Delhi (India)
- Annual Revenue: ₹1,990Cr as on Mar 31, 2024
- Last Known Valuation: $1.25B as on Sep 06, 2022
- Stage: Acquired
- Total Funding till date: $231M
- Employee Count: 4,552 as on Mar 31, 2025
- Investors: HBM Healthcare Investments, IFC and 36 Others
- Latest Funding Round: Series D, Sep 02, 2022, $40.8M
- Highlight: Acquired
Developer of small molecule therapeutics for treating cancer and rare diseases. The company's lead drug Nirogacestat (PF-03084014), a gamma-secretase inhibitor that helps in treating non-metastatic tumors of connective tissue cells. The second candidate is a MEK 1/2 inhibitor, PF-0325901, for the genetic disorder NF1, one of three genetic conditions known as neurofibromatosis. The 3rd candidate, senicapoc (PF-05416266), also targets a rare condition, hereditary xerocytosis characterized by dehydrated red blood cells.
Key facts about SpringWorks Therapeutics
- Founded Year: 2017
- Location: New York City (United States)
- Stage: Acquired
- Total Funding till date: $230M
- Employee Count: 305 as on Dec 31, 2023
- Investors: HBM Partners, Deerfield and 17 Others
- Latest Funding Round: Post IPO, Sep 07, 2022, $225M
- Highlight: Acquired
3. argenx
Developer of antibody-based drugs to treat autoimmune diseases and cancer. The pipeline includes Oncology-ARGX-110, ARGX-111, ARGX-115, Autoimmunity ARGX-113, and ARGX-110. The proprietary technologies to identify the variable region from the llama's and introduces mutations in the constant region of the antibody for enhanced circulation in the system (NHance) and clearance post-therapy. The company has also developed a non-fucosylated antibody, which enhances antibody-dependent cytotoxicity.
Key facts about argenx
- Founded Year: 2008
- Location: Ghent (Belgium)
- Annual Revenue: €1.34B as on Dec 31, 2022
- Stage: Public
- Total Funding till date: $61.9M
- Employee Count: 355 as on Dec 31, 2022
- Investors: BB Biotech, Avoro Capital Advisors and 20 Others
- Latest Funding Round: Post IPO, Mar 24, 2022, $700M
- Highlight: Public
Developer of small molecule drugs for treating cancer. Its Degronimid platform incorporates highly selective small-molecule binders to target disease-causing proteins and facilitate their rapid destruction and clearance from the cell through the natural proteasome system. It has developed CFT7455 for treating hematologic malignancies, CFT8634 for sarcoma, BRAF V600E for slid tumors.
Key facts about C4 Therapeutics
- Founded Year: 2016
- Location: Cambridge (United States)
- Stage: Public
- Total Funding till date: $223M
- Employee Count: 121 as on Dec 31, 2022
- Investors: Roche, HTIF and 25 Others
- Latest Funding Round: Post IPO, Jan 04, 2024, $25M
- Highlight: Public
5. Ultragenyx
Developer of therapeutics for the treatment of rare and ultra-rare metabolic diseases. The company's lead candidate is Burosumab, a recombinant fully human monoclonal IgG1 antibody indicated for X-Linked Hypophosphatemia (XLH) and Tumor-Induced Osteomalacia (TIO). The next advanced candidate is rhGUS(UX003), a recombinant human beta-glucuronidase (rhGUS), indicated for Mucopolysaccharidosis 7 (MPS 7) or Sly Syndrome which is a lysosomal enzyme deficiency.
Key facts about Ultragenyx
- Founded Year: 2010
- Location: Novato (United States)
- Annual Revenue: $363M as on Dec 31, 2022
- Stage: Acquired
- Total Funding till date: $135M
- Employee Count: 837 as on Dec 31, 2022
- Investors: International Biotechnology Trust, TPG and 9 Others
- Latest Funding Round: Series B, Dec 31, 2012, $75M
- Highlight: Acquired
HBM Healthcare Investments' Year-on-Year Investment Trends
HBM Healthcare Investments has invested in 122 companies over the last 24 years, with an average of 7 new investments annually in the last 10 years. In 2024, it made 5 investments, while as of Apr 2025, it has made 3 investments in this year. Its most recent first time investment was in Curevo and most recent follow-on round was in Fore.
Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2025 (YTD) | 2 | 1 | 3 |
2024 | 2 | 3 | 5 |
2023 | 3 | 3 | 6 |
2022 | 3 | 6 | 9 |
2021 | 13 | 4 | 17 |
2020 | 15 | 5 | 20 |
2019 | 2 | 0 | 2 |
2018 | 8 | 2 | 10 |
2017 | 13 | 2 | 15 |
2016 | 6 | 0 | 6 |
Get HBM Healthcare Investments' portfolio delivered to your inbox!
HBM Healthcare Investments' Investments by Stage
HBM Healthcare Investments has made 31 investments in Series B stage with an average round size of $67.6M, 29 investments in Series C stage with an average round size of $67.2M and 17 investments in Series A stage with an average round size of $57.3M.Note: We have considered here, only first round of investments
Stage of entry | No. of Investments |
|---|---|
Series B | 31 |
Series C | 29 |
Series A | 17 |
Series D | 15 |
Post IPO | 8 |
Others | 9 |
HBM Healthcare Investments' Investments by Sector
HBM Healthcare Investments has a diverse portfolio, with companies operating in the Life Sciences, High Tech, Sustainability Tech, Healthcare and HealthTech. Notably, it has invested in 104 Tech companies, 97 Enterprise (B2B) companies, 7 Software companies and at least 4 companies focusing on Consumer (B2C).
Note: We have considered here, only first round of investments
Sector | No. of Investments |
|---|---|
Life Sciences | 93 |
High Tech | 17 |
Sustainability Tech | 13 |
Healthcare | 11 |
HealthTech | 10 |
Others | 19 |
HBM Healthcare Investments' Investments by Geography
HBM Healthcare Investments has made most investments in United States (73), followed by Germany where it has made 6 investments.
Note: We have considered here, only first round of investments
Country | No. of Investments |
|---|---|
United States | 73 |
Germany | 6 |
Switzerland | 6 |
China | 5 |
India | 3 |
Others | 16 |
HBM Healthcare Investments' recent investments
Filter this listHere are the most recent investments by HBM Healthcare Investments:
Date | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Apr 30, 2025 | United States | Series D | $38M | SR One [+6] | |
Mar 06, 2025 | United States | Series B | $110M | Medicxi [+6] | |
Jan 09, 2025 | Switzerland | Series C | $55M | ||
Aug 08, 2024 | Germany | Series C | $5.46M | Think.Health [+3] | |
May 02, 2024 | United States | Series C | $100M | Khosla Ventures [+8] |
Get the detailed list of all investments by HBM Healthcare Investments. Download now!Unicorns in HBM Healthcare Investments' Portfolio
Filter this listHere is a list of unicorns in HBM Healthcare Investments' portfolio:
Tracxn Score | Company | Short Description | Founded year | Sector | Location | Company Stage | First Investment/ Acquisition Details |
|---|---|---|---|---|---|---|---|
67 | Provider of a deep learning platform for detecting circulating cancer-related markers | 2014 | San Francisco | Series E | vynz{ti |
IPOs and Publicly Listed companies in HBM Healthcare Investments' Portfolio
Filter this listHere are HBM Healthcare Investments' portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Dec 18, 2024 | 2018 | Series C | $4M | |
Oct 11, 2024 | Jun 02, 2022 | Series A | $200M | |
Jul 09, 2024 | - | - | - | |
Jun 28, 2024 | Mar 07, 2024 | Series C | $259M | |
Jan 26, 2024 | Dec 16, 2022 | Series B | $155M |
Acquired companies in HBM Healthcare Investments' Portfolio
Filter this listHere are HBM Healthcare Investments' portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
May 07, 2025 | - | - | - | |
Apr 28, 2025 | - | - | - | |
Jun 06, 2023 | Jun 30, 2014 | Post IPO | $93M | |
Oct 04, 2022 | Jan 11, 2016 | Series C | $48.6M | |
Aug 04, 2022 | Jun 17, 2004 | Series B | $33M |
Team profile of HBM Healthcare Investments
HBM Healthcare Investments has a team of 32 members including 10 Partners and 2 Principals located in Switzerland, China and 2 more locations. HBM Healthcare Investments' team does not sit on the board of any company as of now.Here is a list of top team members in HBM Healthcare Investments:
Name | Designation | Location | Board Memberships | Contact details |
|---|---|---|---|---|
Partner | Zurich | - | ||
Partner | Kussnacht | - | ||
Partner | Cayman Islands | - | - | |
Partner | - | - | - | |
Partner | - | - | - | |
Partner | - | - | - | |
Partner | - | - | - | |
Partner | - | - | - | |
Partner | Lucerne | - | - | |
Partner | Geneva | - | - | |
Principal | Lucerne | - |
Get the full list of HBM Healthcare Investments' team & partners for free. Download now!Co-investors of HBM Healthcare Investments
Over the past 24 years, 846 investors have co-invested in HBM Healthcare Investments's portfolio companies.
- Invested before HBM Healthcare Investments: HBM Partners, Orbimed and 248 others have invested in rounds before HBM Healthcare Investments. There are 9 companies where HBM Partners has invested before HBM Healthcare Investments and 6 companies where Orbimed has invested before HBM Healthcare Investments.
- Top Co-investors of HBM Healthcare Investments: 285 investors entered a company along with HBM Healthcare Investments. These include investors like Orbimed (12 companies).
- Invested after HBM Healthcare Investments: A total of 311 investors have invested in HBM Healthcare Investments's portfolio after their investments. Top Investors include Aisling Capital (5 companies), Orbimed (4 companies) and RA Capital Management (4 companies).
Get full list of HBM Healthcare Investments' co-investors delivered to your inbox!
Recent News related to HBM Healthcare Investments
•
FORE Biotherapeutics Raises $38 Million in Series D FinancingBusiness Wire•May 22, 2025•Fore, SR One, Medicxi, Orbimed and 3 others
•
Curevo Raises $110 Million to Advance Amezosvatein Shingles VaccineBakersfield•Mar 17, 2025•Curevo, Medicxi, Vaxcyte, Vicebio and 12 others
•
HBM Healthcare's Q3 2024/25 report shows key financial figures.WebDisclosure•Jan 20, 2025•HBM Healthcare Investments
•
Numab Therapeutics Announces Series C Extension to CHF 180 Million, Completing Oversubscribed CHF 50 Million FinancingBenzinga•Jan 09, 2025•Numab, Cormorant Capital, HBM Healthcare Investments, Novo Holdings and 4 others
•
Homburger advised Molecular Partners AG in connection with its USD 20 m Underwritten Offering of American Depositary SharesLegal 500•Oct 30, 2024•HBM Healthcare Investments, Homburger, Molecular Partners
•
Molecular Partners prices $20M offeringSeeking Alpha•Oct 25, 2024•Molecular Partners, HBM Healthcare Investments, Leerink Partners, Cowen and 3 others
•
HBM Healthcare Investments publishes Half-Year Report as at 30 September 2024 with key figures for the first six months of the 2024/2025 financial yearWebDisclosure•Oct 21, 2024•HBM Healthcare Investments
•
Strides' CDMO platform raises Rs 801 cr for growthIndiatimes•Oct 17, 2024•Strides Pharma Science, HBM Healthcare Investments, WhiteOak Capital Asset Management, Param Capital and 4 others
•
OneSource Specialty Pharma Limited announced that it has received INR 8.01 billion in funding from Passionate Investment Management Private Limited, Enam Holdings Pvt. Ltd, SBI Life Insurance Company Limited, Param Capital Research Private Limited, White Oak Capital Partners Pte. Ltd., HBM Partners Ltd.Stock Screener•Oct 16, 2024•Strides Pharma Science, HBM Healthcare Investments, White Oak Capital Partners, Param Capital and 1 other
•
Swiss investor HBM leads funding in TPG-backed drugmaker at $1.65 bn valuationVCCircle•Oct 16, 2024•HBM Healthcare Investments, TPG